Cardiovascular Diabetology
Open Access
Journal formatting to fit the target journal guidelines
Experts ensure all elements of your paper match journal formatting guidelines to improve publication success rate!
Aims and Scope
Cardiovascular Diabetology is a peer-reviewed open access medical journal covering the intersection of cardiology and diabetology, meaning the connection between diabetes, metabolic syndrome and cardiovascular diseases. It is published by BioMed Central (a part of Springer Nature since 2008) and was established in 2002, with Enrique Fisman (Tel Aviv University) and Alexander Tenenbaum (Sheba Medical Center) as founding editors-in-chief. Articles are published online upon acceptance, rather than in issues. A printed version is periodically distributed in India by Panacea Biotec Ltd. Less
Key Metrics
View Chart Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
- PublisherBMC
- LanguageEnglish
- FrequencyContinuous publication
- Article Processing ChargesEUR 3090 | USD 3690 | GBP 2790
- Publication Time7
- Editorial Review ProcessAnonymous peer review
- LanguageEnglish
- FrequencyContinuous publication
- Publication Start Year2001
- Publisher URL
- Website URL
- Plagiarism
- Publication Time7
- Waiver Policy
- Editorial Team
- Review ProcessAnonymous peer review
- Review Url
- Author instructions
- Copyright Details
- Deposit PolicySherpa/Romeo
- License typeCC BY, CC0
- OA statement
Ready to spotlight your research findings?
Impress peers and journals alike with a concise, visual summary of your work.
Meets Top Publisher Standards: Essential for leading journals like Elsevier.Enhances Engagement: Research papers with graphical abstracts receive 3X more downloads and 8X more shares.Tailored Just for You: We’ll create a custom graphical abstract based on your manuscript—no sketches needed.
3000+ graphical abstracts produced with 4.8/5 customer rating | Months | % Papers published |
|---|---|
| 0-3 | 59% |
| 4-6 | 36% |
| 7-9 | 4% |
| >9 | 0% |
Topics Covered
Year-wise Publication
- 5Y
- 10Y
FAQs
Since when has Cardiovascular Diabetology been publishing? 
The Cardiovascular Diabetology has been publishing since 2001 till date.
How frequently is the Cardiovascular Diabetology published?
Cardiovascular Diabetology is published Continuous publication.
Who is the publisher of Cardiovascular Diabetology?
The publisher of Cardiovascular Diabetology is BMC.
Where can I find a journal's aims and scope of Cardiovascular Diabetology?
For the Cardiovascular Diabetology's Aims and Scope, please refer to the section above on the page.
How can I view the journal metrics of Cardiovascular Diabetology on editage?
For the Cardiovascular Diabetology metrics, please refer to the section above on the page.
What is the eISSN and pISSN number of Cardiovascular Diabetology?
The eISSN number is 1475-2840 and pISSN number is 1475-2840 for Cardiovascular Diabetology.
What is the focus of this journal?
The journal covers a wide range of topics inlcuding Type 2 diabetes, Oxidative stress, Blood pressure, Insulin resistance, Metformin, Cardiovascular mortality, Thrombus, High-density lipoprotein, Myocardial infarction, Heart failure, Confidence interval, Type 2 Diabetes Mellitus, Reactive oxygen species, Coronary artery calcium, Atrial fibrillation, Stroke, Empagliflozin, Arterial stiffness, Metabolic syndrome, Amputation.
Why is it important to find the right journal for my research?
Choosing the right journal ensures that your research reaches the most relevant audience, thereby maximizing its scholarly impact and contribution to the field.
Can the choice of journal affect my academic career?
Absolutely. Publishing in reputable journals can enhance your academic profile, making you more competitive for grants, tenure, and other professional opportunities.
Is it advisable to target high-impact journals only?
While high-impact journals offer greater visibility, they are often highly competitive. It's essential to balance the journal's impact factor with the likelihood of your work being accepted.